See Brief Summary
Inclusion Criteria * Definite RA with onset at \> 16 years, with total disease duration of at least 6 months * Active disease as manifested by at least 3 joints that are swollen and 6 joints that are tender at time of enrollment, and either an erythrocyte sedimentation rate \>_28, or a CRP \>1.4, or morning stiffness of at least 45 min * Stable dose of DMARDs for 2 mos before baseline visit, with total duration of DMARD for 6 mos. * All standard therapy for RA, including DMARDs and combinations of DMARDs will be allowed as long as doses have been stable for 2 mos * Stable NSAID for 1 month before baseline if on an NSAID * Stable prednisone dose of \< 10 mg/day for 1 month before baseline visit, if on prednisone * Ability to give and understand all elements of informed consent * Absence of comorbid condition which, in the opinion of the physician-investigator, would render the patient unsuitable for the study * Willingness to adhere to the clinical protocol. Exclusion Criteria * A diagnosis of inflammatory arthritis other than rheumatoid arthritis * Chronic anticoagulation * Hypersensitivity to fish or fish products or plant products * A dose of prednisone of \> 10 mg/day, or either a change in the prednisone dose or intra-articular corticosteroid injection within one month of the baseline evaluation * An inability or unwillingness to use an effective form of contraception (females) during the duration of the study * Pregnant and breast-feeding females * Inability or unwillingness to adhere to the study diet * Platelet count \< 100,000/mm 3 * Hemoglobin \< 9 g/dl * Albumin \< 3.3 g
sont désignés dans cette étude